Engineered Enzymes Can Repair Decades of Molecular Aging Damage

Revel Pharmaceuticals engineered an enzyme that removes carboxymethyllysine — a sugar-derived chemical modification of the amino acid lysine — from proteins and restores the residue to normal lysine. It was tested on donated human lens, skin, and arterial tissue in the lab. The significance is that no organism has ever been found with an enzyme capable of this; CML was considered permanent. De Grey emphasizes the enzyme is unknown to nature and never evolved anywhere — it exists only because it was designed. AlphaFold was used extensively to predict the three-dimensional structures of candidate variants.

There is no single intervention that works, and damage repair has to be stacked. His argument against calorie restriction as the answer is specific rather than dismissive. Calorie restriction works poorly in long-lived species for reasons that are evolutionarily well understood, so its mouse results don’t translate — whereas damage-repair approaches shouldn’t suffer that same attenuation. He argues nobody else runs these studies because investors want returns soon and government funders back fashionable, fast-publishing work, and because the studies generate little patentable IP — some of the interventions are off-patent or unpatentable. That’s his stated reason for still running a nonprofit rather than a company.

HUGE breakthrough out today, in arguably the single most neglected aspect of aging, extracellular matrix damage. Top researchers have tried & failed for decades to do this. Massive kudos to Aaron and his team! (Proud to note that Revel is a SENS spinout.) https://t.co/zaVfnoiwVT

— Aubrey de Grey (@aubreydegrey) July 14, 2026

What “rewinding decades of molecular aging” really means

De Grey thinks the headline is defensible rather than hype, but narrowly so. The specific claim is that CML abundance in treated tissue dropped to levels typically seen in a person decades younger. That is one measurable marker returning to a younger-tissue value — not a reduction in biological age. He notes plainly that many other forms of molecular aging, in the extracellular matrix and elsewhere, are untouched by this enzyme. His defense of the phrasing is that CML is a large category, not that it’s the whole picture.

CMLase is an engineered enzyme that specifically reverses Nε-carboxymethyl-lysine (CML) modifications on proteins, restoring the original lysine residues. Researchers at Revel Pharmaceuticals (a SENS Research Foundation spinout), with collaborators at Calico and the University of Colorado, developed it via directed evolution of over 500 million variants starting from a bacterial glycine oxidase scaffold. It successfully reduced CML in model proteins and in donated human lens, skin, and arterial tissues from elderly donors ( over 70% reduction in 75-year-old arterial tissue and over 55% in aged skin, bringing levels below those typical of ~31-year-old tissue). This provides the first proof-of-concept that a form of protein damage long considered irreversible can be enzymatically repaired.

Rewinding decades of molecular aging refers specifically to lowering CML abundance in treated tissues to levels characteristic of much younger individuals. In the experiments, CML in aged human skin was reduced below that of a 31-year-old, and arterial tissue from a 75-year-old showed major clearance—matching the kind of accumulation that builds over decades. Aubrey de Grey notes the headline is reasonably justified for this one molecular mark, though it addresses only one type of aging-related damage among many. It does not claim systemic rejuvenation of the whole organism.

Reversing molecular damage vs. reversing human aging

The gap here is very wide and de Grey doesn’t minimize it. The experiments were performed on donated tissue outside a body; the host opens with an explicit disclaimer that nothing has been tested as a treatment in people. Removing one damage class from excised tissue tells you the chemistry works, not that an organism gets healthier. Aubrey De Grey’s own mouse data is the strongest argument for caution: combining four separate proven interventions still produced only modest life extension, which he attributes to not addressing enough of the things that actually kill the animals.

Extracellular-matrix damage has received less attention because scientific careers and funding favor rapid, high-profile cellular/genetic/epigenetic results. Peer-review grant systems reward frequent publications in top journals, which ECM work (slow, technically demanding, less “fashionable”) rarely delivers quickly. Aubrey de Grey has long argued this creates a systemic bias against important but slower structural-repair research. Philanthropic and company funding (as with Revel) has therefore been essential to keep the area alive.CML is more than a passive biomarker; evidence suggests it can actively drive tissue dysfunction. It binds RAGE and triggers inflammatory signaling, and its accumulation correlates with reduced tissue elasticity and age-related pathology. Exact causal contribution at physiological levels is still being clarified, but the ability to remove it enzymatically now allows direct tests of whether clearance improves function. Aubrey views the main near-term value as validating a platform that can be extended to more clearly pathogenic lesions.Delivering a sizable enzyme protein into dense, intact ECM (artery wall, tendon, lens, kidney) is a major practical challenge. The tightly woven lattice of collagen and elastin may limit access to buried CML sites; ex-vivo experiments used homogenized or thin sections that maximize accessibility. Possible solutions include engineering smaller catalytic molecules, secreting the enzyme from fibroblasts that naturally remodel matrix, or using inducible gene therapy so cells produce and export it locally. Penetration and functional restoration (biomechanics, RAGE signaling) remain untested in living organisms.

doi.org

Immune, delivery, and safety issues include potential immunogenicity of a bacterial-origin enzyme, byproduct generation (H₂O₂ and glyoxylate), and the need for repeated or continuous exposure. Natural clearance systems handle the byproducts at low concentrations, but pharmacokinetics, de-immunization, and off-target effects must be evaluated. Repeated systemic dosing could face antibody responses; gene-encoded inducible versions may reduce that risk. Safety data are currently limited to ex-vivo work.Localized treatments (e.g., topical for skin, intraocular for lens, catheter-delivered for arteries) are likely to reach the clinic earlier than systemic therapies. They avoid many whole-body delivery and immunogenicity hurdles and can still demonstrate functional benefit in accessible tissues. Systemic ECM repair will require more sophisticated delivery or gene-therapy approaches and will therefore take longer.CML is a non-cross-linking adduct on lysine residues; glucosepane is a major intermolecular cross-link between proteins. CML primarily acts as a RAGE ligand and modifies protein chemistry; glucosepane randomly bridges ECM proteins, reducing elasticity and contributing to arterial stiffness and high blood pressure. Glucosepane has been a longstanding SENS target; the CMLase platform is explicitly intended to be adapted to attack such cross-links next.

The success of CMLase opens the door to a library of molecular-repair enzymes for other irreversible age-related modifications. Directed evolution plus AI tools (AlphaFold and the newer AlphaProteo-style inverse design) can generate catalysts for glucosepane, other AGEs, amyloid deposits, or even intracellular lesions. Aubrey notes that once the engineering principles are proven, the “sky is the limit” for creating enzymes nature never evolved. This could systematically address multiple classes of molecular damage.ECM repair would complement partial cellular reprogramming by restoring the structural scaffold that cells live in. Reprogramming primarily resets epigenetic and cellular identity; matrix damage continues to impair tissue mechanics, signaling, and stem-cell niches. Combining the two approaches could yield more complete tissue rejuvenation than either alone—exactly the multi-pronged strategy SENS advocates.The result aligns directly with Aubrey de Grey’s SENS (Strategies for Engineered Negligible Senescence) framework. SENS treats aging as a maintenance problem: periodically repair the seven categories of accumulating damage rather than slow their formation. ECM glycation (especially cross-links) is one of those categories; CMLase is the first practical enzymatic tool that can reverse a previously irreversible lesion in that category. Revel itself originated as a SENS Research Foundation spin-out.The first Robust Mouse Rejuvenation (RMR1) study was a “qualified win.” It combined four interventions (rapamycin, a senolytic, telomerase gene therapy, and young hematopoietic stem-cell transplant) started in mid-life (~18 months) in 1,000 mice and demonstrated clear additivity: the full combination extended mean lifespan more than any single treatment (~4 months beyond controls). It did not, however, break historical maximum-lifespan records set by calorie restriction decades earlier.

Sex differences were pronounced. In females, rapamycin dominated; the combination without it performed little better than controls late in life. In males, true synergy appeared: the full four-treatment group outperformed rapamycin alone across much of the survival curve. This taught that metabolic support (rapamycin) may be needed for animals to tolerate aggressive damage-repair interventions and that sex-specific responses must be designed into future studies.